Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104598
Filing Date
2025-08-07
Accepted
2025-08-07 08:07:42
Documents
54
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rapt-20250630.htm   iXBRL 10-Q 2124991
2 EX-10.1 rapt-ex10_1.htm EX-10.1 272079
3 EX-10.2 rapt-ex10_2.htm EX-10.2 168966
4 EX-10.3 rapt-ex10_3.htm EX-10.3 102081
5 EX-10.4 rapt-ex10_4.htm EX-10.4 117670
6 EX-10.5 rapt-ex10_5.htm EX-10.5 58530
7 EX-31.1 rapt-ex31_1.htm EX-31.1 18595
8 EX-31.2 rapt-ex31_2.htm EX-31.2 18620
9 EX-32.1 rapt-ex32_1.htm EX-32.1 20405
  Complete submission text file 0000950170-25-104598.txt   7592904

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rapt-20250630.xsd EX-101.SCH 776897
57 EXTRACTED XBRL INSTANCE DOCUMENT rapt-20250630_htm.xml XML 1087245
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38997 | Film No.: 251191749
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)